A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2018
Price : $35 *
At a glance
- Drugs Vemurafenib (Primary) ; Acitretin
- Indications Malignant melanoma
- Focus Adverse reactions
- 30 Mar 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 13 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Sep 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.